Madrigal Pharmaceuticals (MDGL) EBIT Growth (1y) (2011 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -36.55% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 99.51% |
| 10 | Madrigal Pharmaceuticals | 15.80 Bn | 14.96 Bn | - | -19.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.29% |
| Mar 31, 2026 | -16.91% |
| Dec 31, 2025 | 11.03% |
| Sep 30, 2025 | 2.00% |
| Jun 30, 2025 | 70.96% |
| Mar 31, 2025 | 47.83% |
| Dec 31, 2024 | 42.82% |
| Sep 30, 2024 | -18.03% |
| Jun 30, 2024 | -88.01% |
| Mar 31, 2024 | -94.08% |
| Dec 31, 2023 | -37.37% |
| Sep 30, 2023 | -22.54% |
| Jun 30, 2023 | -23.02% |
| Mar 31, 2023 | -36.03% |
| Dec 31, 2022 | -32.04% |
| Sep 30, 2022 | -27.31% |
| Jun 30, 2022 | -13.82% |
| Mar 31, 2022 | -8.70% |
| Dec 31, 2021 | -8.47% |
| Sep 30, 2021 | -7.44% |